Introducing new domains of research governance; Govind C. Persad, JD, BS, BA.- Should Research Ethics Encourage the Production of Cost-Effect Interventions?; Rebecca Johnson, MA.- From altruists to Workers: What Claims Should Healthy Participants in Phase I Trials Have Against Trial Employers?; Luana Colloca, PhD.- Nocebo effect: The dilemma of disclosing adverse events; Jan-Ole Reichardt, MA.- Encouraging conscientiousness in risk associated areas of medical research Challenges in common domains of research governance; Sara Anna Suzan Dekking, MAE et al.- Discriminating between Research and Care in Paediatric Oncology. Ethical Appraisal of the ALL- 10 and 11 protocols of the Dutch Childhood Oncology Group (DCOG); Imme Petersen, PhD et al.- What Does the Child’s Assent to Research Participation Mean to Parents? Empirical Findings in Paediatric Oncology in Germany; Marcin Waligóra, PhD.- Assent in paediatric research and its consequences; Rosemarie Bernabe, PhD.- Ethical Issues in Postauthorization Drug Trials; Anette Blümle, PhD et al.- Fate of Clinical Research Studies after Ethical Approval – Follow-Up of Study Protocols until Publication; Daniel Strech, MD, PhD.- et al. Do editorial policies support ethical research? A thematic text analysis of author instructions in psychiatry journals Improving common domains of research governance; Jonathan Kimmelman, PhD.- Risk/Benefit Assessment in Launching Early Human Trials; Annette Rid, MD.- Guidelines for Biomedical Research Involving Human Subjects Setting Thresholds of Acceptable Research Risk: Lessons from the Debate about Minimal Risk; Sapfo Lignou, MSc, MA et al.- Towards an Alternative Account for Defining Acceptable Risk in Non-beneficial Pediatric Research; Roger Brownsword, PhD.- Big biobanks: Three Major Governance Challenges and Some Mini-Constitutional Responses; Bettina Schmietow, MA.- Dynamic Consent to Biobank Research – Paradigm Shift or Red Herring?.